FR1994M - New drug in particular for the treatment of manifestations due to hyperlipemia or hypercholesterolemia. - Google Patents

New drug in particular for the treatment of manifestations due to hyperlipemia or hypercholesterolemia.

Info

Publication number
FR1994M
FR1994M FR906682A FR906682A FR1994M FR 1994 M FR1994 M FR 1994M FR 906682 A FR906682 A FR 906682A FR 906682 A FR906682 A FR 906682A FR 1994 M FR1994 M FR 1994M
Authority
FR
France
Prior art keywords
hyperlipemia
hypercholesterolemia
treatment
new drug
manifestations due
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR906682A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Priority to FR906682A priority Critical patent/FR1994M/en
Application granted granted Critical
Publication of FR1994M publication Critical patent/FR1994M/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
FR906682A 1962-05-15 1962-08-10 New drug in particular for the treatment of manifestations due to hyperlipemia or hypercholesterolemia. Active FR1994M (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR906682A FR1994M (en) 1962-05-15 1962-08-10 New drug in particular for the treatment of manifestations due to hyperlipemia or hypercholesterolemia.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR897592A FR1380417A (en) 1962-05-15 1962-05-15 Novel androstanyl-pyrazoles and method of preparation
FR906682A FR1994M (en) 1962-05-15 1962-08-10 New drug in particular for the treatment of manifestations due to hyperlipemia or hypercholesterolemia.

Publications (1)

Publication Number Publication Date
FR1994M true FR1994M (en) 1963-09-02

Family

ID=8778953

Family Applications (2)

Application Number Title Priority Date Filing Date
FR897592A Expired FR1380417A (en) 1962-05-15 1962-05-15 Novel androstanyl-pyrazoles and method of preparation
FR906682A Active FR1994M (en) 1962-05-15 1962-08-10 New drug in particular for the treatment of manifestations due to hyperlipemia or hypercholesterolemia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR897592A Expired FR1380417A (en) 1962-05-15 1962-05-15 Novel androstanyl-pyrazoles and method of preparation

Country Status (1)

Country Link
FR (2) FR1380417A (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250210A4 (en) * 2015-01-26 2018-08-22 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10172871B2 (en) 2013-04-17 2019-01-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10377790B2 (en) 2013-04-17 2019-08-13 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10391106B2 (en) 2013-04-17 2019-08-27 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
US11993628B2 (en) 2016-07-11 2024-05-28 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241446B2 (en) 2013-04-17 2022-02-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US11261211B2 (en) 2013-04-17 2022-03-01 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US11344563B2 (en) 2013-04-17 2022-05-31 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10172871B2 (en) 2013-04-17 2019-01-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US12201640B2 (en) 2013-04-17 2025-01-21 Sage Therapeutics, Inc. 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof
US10342810B2 (en) 2013-04-17 2019-07-09 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10377790B2 (en) 2013-04-17 2019-08-13 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10391106B2 (en) 2013-04-17 2019-08-27 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11046728B2 (en) 2013-07-19 2021-06-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12071453B2 (en) 2013-08-23 2024-08-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12473327B2 (en) 2014-06-18 2025-11-18 Sage Therapeutics, LLP Neuroactive steroids, compositions and uses thereof
US11780875B2 (en) 2014-06-18 2023-10-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11542297B2 (en) 2014-10-16 2023-01-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US12180248B2 (en) 2014-10-16 2024-12-31 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US12065463B2 (en) 2014-10-16 2024-08-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11530237B2 (en) 2014-10-16 2022-12-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11945836B2 (en) 2014-11-27 2024-04-02 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3250210A4 (en) * 2015-01-26 2018-08-22 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US11147877B2 (en) 2015-01-26 2021-10-19 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11124538B2 (en) 2015-02-20 2021-09-21 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11993628B2 (en) 2016-07-11 2024-05-28 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
US12655175B2 (en) 2016-07-11 2026-06-16 Sage Therapeutics, LLC C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof

Also Published As

Publication number Publication date
FR1380417A (en) 1964-12-04

Similar Documents

Publication Publication Date Title
FR1215M (en) New drug, in particular for the treatment of disorders due to hyperestrogenia or hypoandrogenia.
FR3851M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR3845M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR1438M (en) New drug effective in the treatment of atherosclerosis.
FR1700M (en) New drug in particular for the treatment of manifestations due to hyperlipemia or hypercholesterolemia.
FR126M (en) New drug, in particular for the treatment of postprandial or chronic hyperlipemia.
FR3066M (en) New drug, in particular for the treatment of postprandial or chronic hyperlipemia.
FR1594M (en) New drug in particular for the treatment of hypercholesterolemia and disorders due to acute or chronic hyperlipemia.
FR1979M (en) New drug in particular for the treatment of manifestations due to hyperaldosteronism.
FR1487M (en) New drug in particular for the treatment of disorders due to hyperlipemia.
FR1122M (en) New drug in particular for the treatment of hypercholesterolemia.
FR1764M (en) New drug in particular for the treatment of spasms of coronary or visceral origin.
FR3532M (en) New drug, in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR1259M (en) New drug in particular for the treatment of infections due to staphylococci.
FR23F (en) New drug in particular for the treatment of infections due to staphylococci.
FR3096M (en) New drug in particular for the treatment of states of adynamia.
FR3031M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR2746M (en) New drug for the treatment of uric acid elimination disorders.
FR2656M (en) New drug, in particular for the treatment of chronic or postprandial hyperlipemia.
FR1203M (en) New drug, in particular for the treatment of disorders due to hyperestrogenia or hypoandrogenism.
FR2789M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR2458M (en) New drug in particular for the treatment of depressive states or anxiety.
FR1288M (en) New drug, in particular for the treatment of postprandial or acute hyperlipemia.
FR385M (en) New drug for the treatment of staphylococcal infections and the like.
FR2681M (en) New drug in particular for the treatment of spasms of coronary origin.